Chronic Idiopathic Constipation

Gattex® (teduglutide)

• opens in a new tabLong-Term Safety and Effectiveness of Teduglutide in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure: An Observational, Prospective, Multicenter Registry

Eohilia® (budesonide)

• opens in a new tabSafety of short-term therapy with budesonide oral suspension for eosinophilic esophagitis: an integrated analysis of adolescent safety data

Entyvio® (vedolizumab)

• opens in a new tabInvestigating the Relationship Between Endoscopic Characteristics and Treatment Choice for Patients with Ulcerative Colitis Using a Real-world Data Set Linked to Endoscopic Videos Evaluated with Computer Vision
• opens in a new tabComparative Efficacy of Biologics for the Induction of Clinical Remission and Response in Biologic-naïve Patients with Moderate to Severe Crohn’s Disease: Outcomes from Frequentist and Bayesian Network Meta-analyses
• opens in a new tabComparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel disease therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis
• opens in a new tabReal-World Effectiveness and Onset of Action of Vedolizumab as a First-Line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
• opens in a new tabIdentification of Moderate Disease Severity Definitions for Crohn’s Disease and Ulcerative Colitis: A Review of Phase 3 Trials of Pharmacological Therapy

Eohilia® (budesonide)

• opens in a new tabEffect of budesonide oral suspension on dysphagia symptom resolution and time to first dysphagia symptom response in eosinophilic esophagitis: post hoc analysis of phase 2 and phase 3 trial placebo-controlled trials
• opens in a new tabEffect of budesonide oral suspension on dysphagia symptom outcomes in patients with eosinophilic esophagitis: a pooled post hoc analysis of data from a phase 2 and a phase 3 trial

Eohilia® (budesonide)

• opens in a new tabEffect of budesonide oral suspension on dysphagia severity outcomes in patients with eosinophilic esophagitis
• opens in a new tabEffect of corticosteroid use on outcomes in patients with eosinophilic esophagitis receiving budesonide oral suspension

Entyvio® (vedolizumab)

• opens in a new tabDevelopment of a risk adjustment model in commercially insured patients with inflammatory bowel disease

Gattex® (teduglutide)

• opens in a new tabLong-term Safety and Effectiveness of Teduglutide in Paediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure: an Observational, Prospective, Multicentre Registry

Gattex® (teduglutide)

• opens in a new tabLong-term Safety & Effectiveness of Teduglutide in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure: A Multicenter Registry

Entyvio® (vedolizumab)

• opens in a new tabProactive Patient Engagement to Promote Representative Patient Populations for Future Trials of Dual Targeted Therapies in Inflammatory Bowel Diseases

Eohilia® (budesonide)

• opens in a new tabSafety of short-term therapy with budesonide oral suspension for eosinophilic esophagitis: an integrated analysis of phase 2 and 3 clinical studies

Eohilia® (budesonide)

• opens in a new tabEffect of food on the pharmacokinetics, safety and tolerability of budesonide oral suspension in healthy adults: a randomized phase 1 study

Gattex® (teduglutide)

• opens in a new tabLong-term Safety of Teduglutide in Paediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure: an Observational, Prospective, Multicentre Registry
• opens in a new tabLong-term Effectiveness of Teduglutide in Paediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure: an Observational, Prospective, Multicentre Registry

Gattex® (teduglutide)

• opens in a new tabShort bowel syndrome patient experience: a mixed-method study leveraging Inspire, an online community platform.

Entyvio® (vedolizumab)

• opens in a new tabProactive patient engagement to promote representative patient populations for future trials of dual targeted therapies in inflammatory bowel diseases.
• opens in a new tabMachine Learning-Based Precision Medicine Approach Identifies Specific Responder Sub-Populations in the Vedolizumab treated patients by Dynamic Clustering of PRO Data: Post Hoc Analysis of VARSITY and GEMINI Dataset.
• opens in a new tabBiologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab [encore].
• opens in a new tabReal-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease by disease location: Results from the EVOLVE Expansion study [encore].

Eohilia® (budesonide)

• opens in a new tabSafety of short-term therapy with budesonide oral suspension for eosinophilic esophagitis: an integrated safety analysis of four phase 1–3 clinical studies.

Motegrity® (prucalopride)

• opens in a new tabDiagnostic journey of patients with chronic idiopathic constipation in the USA: analysis from a cross-sectional observational study.

Eohilia® (budesonide)

• opens in a new tabImproved histopathologic features in patients with eosinophilic esophagitis: data from a phase 3, randomized, placebo-controlled trial of budesonide oral suspension